AACR 2023 | The current status of tissue agnostic therapies

Mohamed Gouda, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview of tissue agnostic therapies, where they emphasize the role of molecular profiling in choosing the best therapy for patients, as opposed to tumor site and histology. There are currently five targets (tumor mutational burden [TMB] high, deficient mismatch repair [dMMR], NTRK fusions, RET fusions, and BRAF V600E mutations), as well as six drugs approved by the FDA. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.